Zolinza

(vorinostat)

ApprovedSmall molecule

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Vorinostat is used to treat a type of cancer called cutaneous T-cell lymphoma, which affects skin cells and causes lesions or tumors on the skin.[2] Zolinza is currently approved and in use across 37 indications[4].[1]

Zolinza is one of 589 small molecule programs targeting Polycythemia Vera. It is currently in Approved.

Indications

230

Total Trials

Active Trials

588

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Polycythemia VeraApproved

Follicular Thyroid CarcinomaApproved

Iris MelanomaApproved

Non-Hodgkins LymphomaApproved

Unspecified Peripheral T-Cell LymphomaApproved

LeukemiaCompleted

MesotheliomaApproved

Alzheimer DiseaseApproved

Hodgkins LymphomaApproved

NeuroblastomaNot yet recruiting

Polycythemia VeraApproved

Approved

Follicular Thyroid CarcinomaApproved

Approved

Iris MelanomaApproved

Approved

Non-Hodgkins LymphomaApproved

Approved

Unspecified Peripheral T-Cell LymphomaApproved

Approved

LeukemiaPhase 1

Completed

MesotheliomaApproved

Approved

Alzheimer DiseaseApproved

Approved

Hodgkins LymphomaApproved

Approved

NeuroblastomaPhase 2

Not yet recruiting

Showing 10 of 37 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

13 2

Lexiscan

Astellas

Preclinical

1 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Spravato

WWim Janssens

Preclinical

2 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 9

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 10

Ablavar

LLantheus Medical Imaging

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Breast Cancer

NCT03742245

Q1 2027

Phase 1Recruiting

Chemotherapy

NCT05317403

Phase 2Active, not recruiting

Breast Cancer

NCT00616967

Q3 2028

Phase 2/3Active, not recruiting

Acute Lymphoblastic Leukemia

NCT03117751

Q4 2033

Phase 1/2Recruiting

Acute Lymphoblastic Leukemia

NCT05848687

Clinical

Trials by Indication[1]

Lymphoma18 trials

Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT00561418·23 enrolled

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00499811·15 enrolled

Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Completed·FFox Chase Cancer Center·Phase 1·NCT01169532·16 enrolled

Show 15 more trials

Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Terminated·—·Phase 1·NCT01116154·30 enrolled

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00992446·27 enrolled

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01567709·34 enrolled

A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00127140·10 enrolled

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00810576·1 enrolled

Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma

Completed·UUniversity of Rochester·Phase 1·NCT01276717·20 enrolled

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01132911·5 enrolled

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

Completed·—·Phase 2·NCT00720876·30 enrolled

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00994500·20 enrolled

Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00132028·27 enrolled

Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00253630·37 enrolled

Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01983969·61 enrolled

Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas

Terminated·YYale University·Phase 1/2·NCT00785798·17 enrolled

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01193842·107 enrolled

Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT01120834·17 enrolled

Breast Cancer13 trials

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

Completed·UUniversity of Washington·N/A·NCT01153672·8 enrolled

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00616967·68 enrolled

Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy

Completed·—·Phase 1/2·NCT00574587·55 enrolled

Show 10 more trials

Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00132002·14 enrolled

HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer

Completed·YYale University·Phase 1·NCT00719875·24 enrolled

Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00262834·54 enrolled

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

Terminated·UUniversity of California, San Francisco·Phase 2·NCT04190056·1 enrolled

Clinical Trial of SAHA in Patients With Breast Cancer

Unknown status·NNational University Hospital, Singapore·Phase 1/2·NCT00416130·49 enrolled

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

Completed·UUniversity of Washington·N/A·NCT01720602·15 enrolled

GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers

Terminated·UUniversity of Maryland, Baltimore·Phase 1/2·NCT01118975·12 enrolled

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Active, not recruiting·TThe Methodist Hospital Research Institute·Phase 1·NCT03742245·28 enrolled

Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00368875·54 enrolled

Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00258349·16 enrolled

Multiple Myeloma12 trials

Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy

Withdrawn·TTiziana Marangon·Phase 2·NCT01501370

Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)

Completed·UUniversity Hospital Freiburg·Phase 1/2·NCT01394354·34 enrolled

Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00111813·34 enrolled

Show 9 more trials

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00744354·32 enrolled

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00773747·637 enrolled

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00310024·40 enrolled

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00839956·31 enrolled

Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00858234·9 enrolled

Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT00729118·19 enrolled

Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients

Terminated·TTiziana Marangon·Phase 1/2·NCT00857324·18 enrolled

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

Completed·EEmory University·Phase 1·NCT01038388·30 enrolled

Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00642954·31 enrolled

Non-Small Cell Lung Cancer8 trials

Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed·FFox Chase Cancer Center·Phase 1·NCT01059552·18 enrolled

Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00481078·94 enrolled

Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer

Completed·SStanford University·Phase 1·NCT00946673·17 enrolled

Show 5 more trials

A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2/3·NCT00473889·253 enrolled

Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00138203·16 enrolled

Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00798720·18 enrolled

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01413750·23 enrolled

Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer

Completed·YYale University·Phase 1·NCT00821951·17 enrolled

Acute Lymphoblastic Leukemia5 trials

Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01312818·2 enrolled

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Recruiting·TTanja Andrea Gruber·Phase 1/2·NCT05848687·90 enrolled

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2/3·NCT03117751·790 enrolled

Show 2 more trials

Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

Completed·—·Phase 1·NCT00816283·5 enrolled

Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00882206·15 enrolled

92 more indications

Glioblastoma Multiforme5 trials

Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00641706·44 enrolled

Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT00555399·55 enrolled

Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01110876·21 enrolled

Show 2 more trials

Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00731731·125 enrolled

Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00238303·103 enrolled

Advanced Cancer5 trials

Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

Completed·UUniversity of Colorado, Denver·Phase 1·NCT00635791·36 enrolled

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00750178·30 enrolled

Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01266057·143 enrolled

Show 2 more trials

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00045006

A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00632931·25 enrolled

Myelodysplastic Syndrome4 trials

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00818649·16 enrolled

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01130506·17 enrolled

Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00656617·106 enrolled

Show 1 more trial

Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00948064·110 enrolled

Glioblastoma4 trials

Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma

Completed·NNational Cancer Institute (NCI)·N/A·NCT01342757·12 enrolled

A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00762255·19 enrolled

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03426891·21 enrolled

Show 1 more trial

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01266031·96 enrolled

Myelodysplastic Syndromes3 trials

Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01593670·9 enrolled

Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00331513·40 enrolled

Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00486720·22 enrolled

Acute Myeloid Leukemia3 trials

Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00673153·31 enrolled

Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)

Completed·SSteven E. Coutre·Phase 2·NCT01550224·23 enrolled

Vorinostat in Treating Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00305773·37 enrolled

Kidney Cancer3 trials

Vorinostat in Treating Patients With Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00278395·14 enrolled

Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00324740·14 enrolled

Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00324870·37 enrolled

Neuroblastoma3 trials

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

No longer available·—··NCT01838187

N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT01019850·27 enrolled

Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01208454·29 enrolled

Pancreatic Cancer3 trials

Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 1·NCT00983268·21 enrolled

Vorinostat Plus Radiation Therapy in Pancreatic Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT00831493·3 enrolled

Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer

Completed·VVirginia Commonwealth University·Phase 1·NCT02349867·23 enrolled

Cutaneous T-cell lymphoma3 trials

Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

Terminated·UUniversity of Washington·Phase 2·NCT00958074·11 enrolled

Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

Withdrawn·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT01386398

An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT00127101·23 enrolled

Relapsed or Refractory3 trials

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00895934·52 enrolled

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01076530·27 enrolled

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01421173·78 enrolled

Mycosis Fungoides3 trials

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

Terminated·MmiRagen Therapeutics, Inc.·Phase 2·NCT03713320·37 enrolled

Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides

Terminated·SStanford University·Phase 1/2·NCT01187446·28 enrolled

Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides

Unknown status·AAngimmune LLC·Phase 2·NCT02943642·162 enrolled

Unresectable Solid Tumor3 trials

Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00243100·21 enrolled

Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·UUniversity Health Network, Toronto·Phase 1·NCT00121277·28 enrolled

Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00227513·66 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00703664·65 enrolled

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT02589145·8 enrolled

Malignant Pleural Mesothelioma2 trials

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00128102·661 enrolled

A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma

Withdrawn·UUniversity College, London·Phase 1/2·NCT01353482

Chronic Myelogenous Leukemia2 trials

Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00278330·24 enrolled

Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00275080·80 enrolled

Patients With Solid Tumors2 trials

A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00373490·16 enrolled

A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00127127·18 enrolled

Refractory Solid Tumors2 trials

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

Unknown status·NNew York Medical College·Phase 1·NCT04308330·30 enrolled

Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00287937·30 enrolled

Patients With Advanced Solid Tumors2 trials

Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00324480·60 enrolled

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00005634

HIV infection2 trials

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection

Completed·SSEARCH Research Foundation·Phase 1/2·NCT02475915·15 enrolled

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

Terminated·AAIDS Malignancy Consortium·Phase 1·NCT01249443·17 enrolled

Chemotherapy2 trials

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT01483690·23 enrolled

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Recruiting·MMedical College of Wisconsin·Phase 1·NCT05317403·40 enrolled

Chronic Lymphocytic Leukemia2 trials

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00764517·57 enrolled

Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00918723·40 enrolled

Diffuse Intrinsic Pontine Glioma2 trials

Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01189266·79 enrolled

Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02420613·18 enrolled

Metastatic Prostate Cancer2 trials

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Terminated·RRoswell Park Cancer Institute·Phase 1·NCT01174199·13 enrolled

Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00330161·29 enrolled

Lung Cancer2 trials

A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT00251589·23 enrolled

Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery

Terminated·UUniversity of Washington·Phase 1/2·NCT00662311·5 enrolled

Colorectal Cancer2 trials

Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT02316340·42 enrolled

Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00138177·54 enrolled

T-cell non-Hodgkin lymphoma2 trials

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT04220008

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Completed·UUniversity of Washington·Phase 1/2·NCT00601718·29 enrolled

HIV2 trials

Research In Viral Eradication of HIV Reservoirs

Completed·IImperial College London·Phase 2·NCT02336074·60 enrolled

Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy

Unknown status·BBayside Health·Phase 2·NCT01365065·20 enrolled

Melanoma2 trials

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

Completed·TThe Netherlands Cancer Institute·Phase 1/2·NCT02836548·33 enrolled

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00121225·32 enrolled

Graft Vs Host Disease2 trials

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Active, not recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT03842696·43 enrolled

Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT01790568·26 enrolled

Glioma2 trials

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Completed·NNational Cancer Institute (NCI)·Phase 2/3·NCT01236560·101 enrolled

High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01378481·30 enrolled

Soft Tissue Sarcoma2 trials

Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)

Completed·HHeidelberg University·Phase 2·NCT00918489·40 enrolled

Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00937495·16 enrolled

Recurrent or Metastatic1 trial

Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00363883·14 enrolled

Relapse1 trial

Epigenetic Reprogramming in Relapse AML

Terminated·MMichael Burke·Phase 1·NCT02412475·3 enrolled

Ductal Carcinoma in Situ1 trial

Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast

Completed·UUniversity of California, San Francisco·Phase 1·NCT00788112·17 enrolled

Advanced NSCLC1 trial

Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00423449·61 enrolled

Leukemia1 trial

Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00217412·60 enrolled

Myelodysplasia1 trial

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

Completed·GGroupe Francophone des Myelodysplasies·Phase 1/2·NCT00776503·52 enrolled

Intestinal Cancer1 trial

Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT00537121·23 enrolled

Malignancies1 trial

MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02042989·68 enrolled

High Risk1 trial

Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS

Completed·UUniversity of Birmingham·Phase 2·NCT01617226·260 enrolled

Uveal Melanoma1 trial

Vorinostat in Patients With Class 2 High Risk Uveal Melanoma

Withdrawn·UUniversity of Miami·Phase 1·NCT03022565

Metastasis1 trial

Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis

Terminated·NNational Taiwan University Hospital·Phase 2·NCT01600742·4 enrolled

Radiation Therapy1 trial

Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT00838929·17 enrolled

Sickle Cell Disease1 trial

Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

Terminated·—·Phase 2·NCT01000155·5 enrolled

Advanced Sarcoma1 trial

Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma

Completed·UUnknown Sponsor·Phase 1/2·NCT01879085·37 enrolled

Triple-Negative Breast Cancer1 trial

Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer

Withdrawn·UUniversity of Southern California·N/A·NCT01695057

Hematologic Cancer1 trial

Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00357708·50 enrolled

Adenocarcinoma1 trial

Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas

Terminated·MMassachusetts General Hospital·Phase 1/2·NCT00948688·10 enrolled

Adenoma1 trial

Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease

Withdrawn·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT04339751

Locally Advanced Solid Tumor1 trial

Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00331955·40 enrolled

Ovarian Cancer1 trial

Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

Terminated·—·Phase 1/2·NCT00910000·15 enrolled

T Cells1 trial

The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1/2·NCT01319383·25 enrolled

Adenoid Cystic Carcinoma1 trial

Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01175980·30 enrolled

Hematologic Malignancies1 trial

Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02419755·12 enrolled

Refractory AML1 trial

Epigenetic Reprogramming in Relapse/Refractory AML

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT03263936·37 enrolled

Resistance1 trial

Reversing Therapy Resistance With Epigenetic-Immune Modification

Terminated·UUniversity of California, San Francisco·Phase 2·NCT02395627·38 enrolled

Prostate Cancer1 trial

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00589472·19 enrolled

Metastatic Colorectal Cancer1 trial

Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00942266·58 enrolled

Graft Versus Host Disease1 trial

Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant

Completed·—·Phase 1/2·NCT00810602·61 enrolled

Von Hippel-Lindau Disease1 trial

Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT02108002·7 enrolled

Radiotherapy1 trial

Vorinostat and Palliative Radiotherapy

Completed·OOslo University Hospital·Phase 1·NCT00455351·15 enrolled

Advanced Solid Tumors1 trial

Hydroxychloroquine + Vorinostat in Advanced Solid Tumors

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT01023737·72 enrolled

Malignant Glioma1 trial

Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients

Completed·—·Phase 2·NCT01738646·48 enrolled

HIV-1 infection1 trial

Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT02707900·6 enrolled

Hematological Malignancies1 trial

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01789255·12 enrolled

Relapsed/Refractory1 trial

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Completed·KKyowa Kirin, Inc.·Phase 3·NCT01728805·372 enrolled

Metastatic Head and Neck Cancer1 trial

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01267240·25 enrolled

Salivary Gland Cancer1 trial

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

Completed·UUniversity of Washington·Phase 1/2·NCT02538510·50 enrolled

Combination Therapy1 trial

Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT03803605·15 enrolled

Uterine Sarcoma1 trial

Vorinostat (SAHA) in Uterine Sarcoma

Terminated·MMedical University of Graz·Phase 2·NCT03509207·3 enrolled

Solid Malignancies1 trial

Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT00565227·12 enrolled

Epilepsy1 trial

Voronistat in Pediatric Patients With Drug Resistant Epilepsy

Unknown status·UUniversity of Calgary·Phase 2·NCT03894826·12 enrolled

Primary Peritoneal Cavity Cancer1 trial

Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00132067·60 enrolled

Sorafenib1 trial

Study of Curcumin, Vorinostat, and Sorafenib

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT01608139

Myeloproliferative Disorder1 trial

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00357305·25 enrolled

Squamous Cell Carcinoma1 trial

Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT01064921·27 enrolled

Thyroid Cancer1 trial

Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00134043·19 enrolled

Clinical Trial1 trial

A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer

Completed·—·N/A·NCT00735826·10 enrolled

Acute Leukemia1 trial

Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02083250·70 enrolled

Liver Cancer1 trial

Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer

Completed·VVirginia Commonwealth University·Phase 1·NCT01075113·16 enrolled

Advanced Cancers1 trial

A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00907738·27 enrolled

Lymphoid Malignancies1 trial

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

Completed·—·Phase 1·NCT00691210·40 enrolled

Viremia1 trial

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT05700630

Trial1 trial

Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00479232·71 enrolled

Ovarian Carcinoma1 trial

Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma

Terminated·GGynecologic Oncology Associates·Phase 1/2·NCT00976183·18 enrolled

Niemann-Pick disease1 trial

Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 1/2·NCT02124083·12 enrolled

Locally Advanced1 trial

Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC

Withdrawn·—·Phase 2·NCT05608369

Pembrolizumab1 trial

Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma

Completed·NNabil Adra·Phase 1·NCT02619253·52 enrolled

Histone Deacetylase Inhibitor1 trial

Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03382834·31 enrolled

Mantle Cell Lymphoma1 trial

Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00875056·56 enrolled

Unspecified2 trials

MIBG With Dinutuximab +/- Vorinostat

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT03332667·45 enrolled

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 2·NCT02035137·114 enrolled

Regulatory

FDA Approval Timeline[5]

Oct 6, 2006

ZOLINZA

NDA NDA021991

Sources

References

[1]
ClinicalTrials.gov — 230 trial records for vorinostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Zolinza drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — vorinostat compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for vorinostat. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021991). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Zolinza. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Histone Deacetylase 2 Inhibitor; Histone Deacetylase 1 Inhibitor; Histone Deacetylase 3 Inhibitor; Histone Deacetylase 6 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Patent Landscape[6]

Patent Cliff

Mar 11, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8093295May 16, 2026

7456219Mar 11, 2027

8450372Mar 18, 2028